First line immunotherapy combination fails to improve overall survival in lung cancer

First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.(1) The combination of immune checkpoint inhibitors and chemotherapy has been successfully tested in different trials as first line therapy for
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news